In our study, SETD2 mutations in 11q23/KMT2A‐rearranged AML were strongly related with a higher relapse rate, suggesting that a more aggressive approach such as allogeneic HSCT or novel therapeutic strategies should be considered in the early stage of treatment. The gene discussed is SETD2; the disease is acute myeloid leukemia.